Growing animal data implicate cholecystokinin in the regulation of anxiety, while human clinical research confirms the role of cholecystokinin in the provocation of panic attacks. Antipanic medications suppress the ability of cholecystokinin to induce panic attacks, and may alter the expression of the cholecystokinin gene. Thus, there is increased interest in understanding the molecular genetic component of these observations. Recent association studies using persons with panic disorder described some association between polymorphisms in the genes encoding cholecystokinin and the cholecystokinin B-receptor and panic disorder. In this study, we used a family-based design, employing 596 individuals in 70 panic disorder pedigrees, as well as 77 haplotype relative risk 'triads'. Subjects were genotyped for two polymorphisms: the polymorphic microsatellite marker in the CCK-BR locus using PCR-based genotyping and at a single nucleotide polymorphism in the CCK promoter using a fluorescence polarization detection assay, and the data were analyzed for genetic association and linkage. Employing a variety of diagnostic and genetic models, linkage analysis produced no significant lod scores at either locus. Family-based tests of association, the haplotype-based haplotype relative risk statistic and the transmission disequilibrium test, were likewise nonsignificant. The results reported here provide little support for the role of these polymorphisms in panic disorder. Molecular Psychiatry (2001) 6, 59-65.
Introduction
It is estimated that between 1 and 3% of the population suffers from panic disorder during their lifetime. 1 Persons with this disorder suffer from recurrent panic attacks, experienced as spontaneous crescendo peaks of anxiety, with somatic and psychological symptoms, accompanied by anticipatory anxiety. A number of family studies show that first degree relatives of persons with panic disorder have a 2.6-19.5-fold relative risk of having panic disorder compared to controls, 2 with this risk being increased in families of probands with early onset 3 or with smothering symptoms. 4 A smaller number of twin studies have reported that heritable factors contribute about 30-40% of the liability towards panic disorder. 5 Recent segregation analyses suggest that recessive and dominant modes of inheritance are equally likely, and that panic disorder is unlikely to have a simple Mendelian inheritance. 6, 7 These genetic factors have been the focus of recent work employing genome-wide 8 and candidate gene strategies. [9] [10] [11] [12] [13] [14] Although the psychobiology of panic disorder is a mystery, several lines of evidence underscore a developing understanding of the pathophysiology. First, the utility of medications in treating panic disorder suggests the involvement of various neurotransmitter systems, including noradrenergic and serotoninergic circuits. Additional insight into the disorder has been gained from challenge studies, in which panic is provoked differentially in panic disorder patients when compared to normal controls after ingestion, inhalation, or injection of anxiogenic substances (see Bourin et al for review). 15 The peptide cholecystokinin (CCK) is one such panicogenic agent. Injection of a tetrapeptide (CCK-4) derived from the full CCK sequence induces panic attacks in normal controls 16 and in persons with panic disorder, 17 with persons with panic being much more sensitive than controls to the effects of CCK-4. 18 Likewise, agonists to the CCK-B receptor differentially induce panic in those with panic disorder when compared to controls. 19 Antagonists to this receptor have a more variable effect, with one study showing that such an agent could attenuate CCK-4-provoked panic attacks, 20 while other studies showed that such an antagonist was not efficacious in reducing panic attacks. [21] [22] [23] Further, antipanic agents like imipramine, fluvoxamine, and citalopram suppress CCK-4-mediated panic attacks. [24] [25] [26] Additionally, there appear to be pharmacologic and neuroendocrine differences between CCK-induced panic attacks and those precipitated by lactate or carbon dioxide. In light of these observations, the CCK system has been the focus of molecular genetics research, with one report, by Crowe et al, 14 of a polymorphism in a potential binding site for the regulatory transcription factor SP1 in the promoter of the CCK gene, showing marginal association to panic disorder. Recently, a positive association between panic disorder and alleles of the CCK-B receptor, but not the CCK-A receptor or CCK promoter polymorphism, was reported in a case-control study design by Kennedy and colleagues. 27 An earlier study investigating a missense mutation elsewhere in the CCK-B receptor gene found no association to panic disorder. 12 This current study utilizes a family-based design to ascertain any linkage or association between the single nucleotide polymorphism (SNP) in the SP1 site of the CCK gene and a simple sequence repeat in the CCK B receptor (CCKBR), and panic disorder.
Methods and materials

Subjects
Families were recruited from several sources, including anxiety clinics, therapists specializing in treating anxiety disorders, and anxiety disorder support groups/associations. Initially, families with at least three affected persons were asked to participate. Participants underwent interviews utilizing the Schedule for Affective Disorders and Schizophrenia-Lifetime Version for Anxiety Disorders, Revised 28 and the Family Informant Schedule and Criteria, 29 from which DSM-III-R diagnoses of panic disorder with recurrent spontaneous panic attack ± agoraphobia were derived, as previously described. 8, 30 In this study, 77 association triads consisting of proband, mother, and father were genotyped with both markers. In two of the triads, a concurrent psychiatric condition such as depression or alcohol dependence was noted. In addition, 587 individuals and 596 individuals in 70 multiplex families were genotyped with CCKBR and CCK, respectively.
DNA analysis
CCKBR Preparation of the DNA samples was as described elsewhere. 8 Polymerase chain reaction (PCR) was performed as described. 31 Briefly, PCR reactions of 15 microliters (l) containing 1 M of the forward and reverse primers (Fam-labeled CCKBR-F, 5Ј AAACCTC CCCCTACGCTG-3Ј, and CCKBR-R, 5Ј-CCTAGATG TGTCCCGTCTCC-3Ј), 100 ng DNA template, 200 M dNTPs, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , and 0.5 units Platinum Taq DNA polymerase (GibcoBRL, Grand Island, NY, USA), were cycled at 94°C for 3 min, followed by 25 cycles of 94°C for 60 s, 57°C for 30 s, and 72°C for 90 s, with a final 5 min at 72°C. The reactions were performed on a MJ Research PTC-200 Thermal Cycler in 96-well plates (Costar, Corning, NY, USA). PCR products were then separated by electrophoresing on 4% polyacrylamide gels using an ABI 377 DNA Sequencer. PCR products were sized using TMR-labeled standards (BioVentures Inc, Murfreesboro, TN, USA), and genotypes analyzed using GENESCAN and GENOTYPER software (Applied Biosystems, Foster City, CA, USA). Since our primers and allele numbering system differ from those described by Kennedy and colleagues, we obtained six DNA samples of known CCKBR genotype from them to allow us to place our observed alleles in register with those observed to increase risk for panic disorder. 27 CCK A SNP in the 5Ј untranslated region of the CCK gene was assayed using fluorescence polarization detection of template-directed dye-terminator incorporation (FP-TDI), essentially as described. 32 This method is a homogenous assay employing the highly sensitive and specific template-directed primer extension technique. Briefly, 20 ng of genomic DNA was first amplified in 10 l, using 1.5 mM MgCl 2 , 1 M anhydrous betaine, 20 mM Tris (pH 8.4), 50 mM KCl, 25 M dNTP, 100 nM primer (CCK-F, 5Ј-GGATTAACT GGACCCCACTAGACCACCTCC-3Ј, CCK-R, 5Ј-GGGA CCTACCTTTTGGATTAGGACTGGCAGC-3Ј), and 1 unit of Platinum Taq DNA polymerase (GibcoBRL). The reaction was cycled by using a touchdown protocol by starting at 94°C for 3 min, followed by 10 cycles of 94°C for 30 s, 65-55°C for 30 s (decreasing by 1°C intervals per cycle), and 72°C for 30 s, followed by 30 cycles of 90°C for 30 s, 55°C for 30 s, and 72°C for 30 s, with a final 10 min at 72°C. The reactions were performed on an MJ Research PTC-200 Thermal Cycler in 96-well plates (Costar). The remaining primers and dNTPs were degraded by adding to the PCR product a 10-l aliquot containing 2 units of shrimp alkaline phosphatase (SAP) (Roche Molecular Biochemicals, Indianapolis, IN, USA) and 1 unit of E. coli exonuclease 1 (Exo1) (Amersham Pharmacia Biotech, Piscataway, NJ, USA) in SAP buffer (50 mM Tris-HCl (pH 8.5) and 5 mM MgCl 2 ). This reaction was incubated for 90 min at 37°C, followed by inactivation at 95°C for 15 min. To this reaction 10 l of the FP-TDI mix of 50 mM TrisHCl (pH 9.0), 50 mM KCl, 5 mM NaCl, 5 mM MgCl 2 , 8% glycerol, 0.1% Triton X-100, 125 nM of BODIPY fluorescein-ddATP and R6G-ddGTP, 125 nM of unlabelled ddCTP and ddTTP, 1.0 M primer (CCK-Probe, 5Ј-GGGCGGCTGTCT CTTAAATAGCCCC-3Ј), and 0.8 units of Thermosequenase DNA polymerase (Amersham Pharmacia) were added. This mixture was incubated at 95°C for 2 min, followed by cycling 35 times at 94°C for 15 s and 55°C for 30 s, and then held at 4°C until the next step. Fluorescence polarization was measured by transferring 10 l of the primer exten-sion reaction to a microtiter plate and reading on an Analyst AD high-throughput fluorescence detection platform (LJL BioSystems, Sunnyvale, CA, USA). The FP values were derived as described, 32 and expressed in the dimensionless unit, mP. The ability to detect this C/T substitution was confirmed using DNAs genotyped using a single-strand conformational polymorphism technique (typed DNAs kindly provided by Dr RR Crowe) and by DNA sequencing of four individuals of each of the three possible genotypes.
Data analysis
Pedigrees were analyzed for linkage using both dominant and recessive genetic models of inheritance and a penetrance of 50%, assuming both genetic heterogeneity and homogeneity, under three diagnostic models (narrow, intermediate, and broad) using the FASTLINK package. 33, 34 The parametric analyses were performed allowing for a reduced penetrance (50%) and a phenocopy rate of 1%, with a disease allele frequency of 0.01. Calculations of lod scores under models of genetic heterogeneity were carried out with the HOMOG program. 35 In the 'narrow' model individuals who are diagnosed as having 'definite' or 'probable' panic disorder are coded as affected. The 'intermediate' model adds individuals diagnosed with 'possible' panic disorder, and the 'broad' model adds those with 'any' panic disorder, as previously described. 10 Affected sibpair analysis, which is a likelihood-based test statistic equivalent to a lod score calculated under simple recessive inheritance, yielding a measure of allele-sharing different from our recessive/dominant genetic models, was performed using the SIBPAIR program in the ANALYZE package. 36 We used both the pedigree data and triad data to test for linkage disequilibrium. We analyzed the pedigree data with the likelihood-based transmission disequilibrium test (TDT-LRT) statistic 37, 38 and analyzed the triad data with both the TDT-LRT 38 and the haplotype-based haplotype relative risk test (HHRR) 39, 40 using the ANA-LYZE package. Both tests allow for multiallelic markers, and they both test for linkage disequilibrium by comparing the distribution of marker alleles between transmitted and non-transmitted alleles against the null hypothesis of equal transmission rates. The TDT-LRT, which asymptotically follows a mixed 2 distribution with 1 degree of freedom, is a likelihood-based method that tests for an increase in association with a single marker allele using information only from heterozygous parents, whereas the marginal homogeneity test, which follows asymptotically a 2 distribution with k − 1 degrees of freedom, where k is the number of marker alleles, allows for more than one marker allele to be positively associated with the disease and uses information from both homozygous and heterozygous parents. Since the CCKBR polymorphism has 17 alleles, however, the asymptotic distribution of the HHRR test is violated due to 35% of our expected cell counts having values less than five. Therefore, we determined the empirical P-values, simulating 500 replications using the CLUMP program. 41 
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Results
CCKBR
A summary of the lod score linkage analysis of the multiplex families is presented in Table 1 . Under the assumptions of genetic homogeneity or heterogeneity, we observed no lod scores greater than 0.31, using recessive or dominant models with three different affectation categories. This is consistent with the results of our genome scan for chromosome 11p15 where all the markers were essentially negative. 8 Using SIBPAIR, a non-parametric test of linkage, we observed non-significant P-values under the three phenotypic models. When the linkage families were subjected to association analysis using TDT-LRT, we observed no significant linkage disequilibrium between CCKBR alleles and panic disorder ( Table 2) .
The frequencies of alleles in the 77 triad probands are presented in Table 3 . The heterozygosity was 0.86, identical to that reported previously. 31 When transmission of the alleles for CCKBR was investigated in 77 triads consisting of both parents and a proband, no preferential transmission of any allele was observed using the TDT-LRT (P = 0.18, not significant (NS), Table 2 ). Of the 154 parents, 136 were heterozygous for the polymorphism, with 24 triads with one heterozygous parent and 56 triads with two heterozygous parents. When using the HHRR statistic in the ANALYZE package, the panic probands did not significantly differ from HHRR 'controls', which are reconstituted from parental alleles (Table 3,   2 = 18.95, df = 16, NS). The allele frequencies within the 70 pedigrees are also shown in Table 3 for comparison. Panic disorder is about twice as frequent in females as males in the general population. 1 Given this observed sex effect, we examined the triads stratified by the sex of the proband (Table 4) . Among both female and male triad probands, there was no association noted between panic disorder and the CCKBR allele ( 2 = 12.89, df = 16, NS; 2 = 17.90, df = 15, NS, respectively). In the case-control study of Kennedy et al, an excess of alleles 6 and 7 was reported in panic disorder patients. Our alleles 8 and 9 are equivalent to their 7 and 6, respectively, and when we assessed these alleles individually against all others, again there was no significant association with panic disorder (data not shown). We did not further group alleles, having no biological justification or a priori hypothesis for doing so.
CCK
Using fluorescence polarimetry, we investigated a previously described SNP in the promoter of the CCK gene, which is postulated to occur in an Sp1 transcriptional regulatory site. The frequency of the T allele was 11.3% (marker heterozygosity of 0.20) among the 137 founders and married-in's in 70 pedigrees, which is close to the population frequency previously described (8.3%).
14 A summary of the lod score linkage analysis of the multiplex families is presented in Table 1 . We observed no lod scores greater than 0.70 under the assumptions of genetic homogeneity or heterogeneity, using recessive or dominant models with three differ- 1  9  6  2  0  2  3  4  0  1  3  3  6  0  1  4  4  4  2  0  5  3  2  3  1  6  5  9  2  3  7  4  4  1  1  8  9  8  1  3  9  3 5  3 0  1 0  9  10  21  20  2  5  11  7  12  6  5  12  9  7  1  0  13  2  3  1  4  14  6  1  2  0  15  0  1  1  0  16  0  2  0  0  17  0  1  0  1 ent diagnostic categories. This is also consistent with the results of our genome scan for chromosome 3p22-p21.3 where all the markers were essentially negative, except a single marker with a Z max of 0.4 at a = 0.3.
8
Using SIBPAIR, we observed non-significant results under all three phenotype models. When the linkage families were subjected to association analysis using TDT-LRT, we observed no significant linkage disequilibrium between CCK alleles and panic disorder. Among the 77 triads, no preferential transmission of either allele was observed using the TDT-LRT (P = 0.5).
Of the 154 parents, 28 were heterozygous for the polymorphism, with 28 triads having one heterozygous parent and no triads having two heterozygous parents. The HHRR statistic showed that the panic probands did not significantly differ from HRR 'controls', which are reconstituted from parental alleles (Table 5,   2 = 0.14, df = 1, NS). We confirmed the accuracy of the assay by double-stranded sequencing of four C/C homozygotes, four T/T homozygotes, and five C/T heterozygotes, all of which were correctly determined by the FP-TDI procedure.
Discussion
The work described here provides no supportive evidence for association or linkage between a polymorphism in either the CCK or CCKBR genes and panic disorder. A large number of analyses using a variety of models showed a consistent picture of the role of these polymorphisms in panic disorder.
A number of possible explanations for our failure to replicate the findings of Kennedy et al exist. First, clinical heterogeneity, given the difference in ascertainment, may lead to concentration of a particular group of persons with panic disorder. For example, the Canadian sample allowed comorbid conditions, while our triad sample included only two probands with concurrent disorders. Additionally, patients were generally recruited for our study on the basis of high familiality of disease, possibly causing us to study a potential discrete subtype of panic disorder. Second, the CCKBR polymorphic locus may be in linkage disequilibrium with a disease-related allele in the Canadian population, but not in our sample.
The third and most likely possibility involves population stratification and admixture. The case-control design of Kennedy et al is susceptible to the effects of population heterogeneity, potentially allowing for false positive findings of differences in allele distribution. Family-based designs, such as that used here, can minimize such errors. A fourth possibility concerns the issue of power. We estimated the power of the TDT for our sample size of 77 triads under various genetic models, assuming zero recombination and a population disease allele frequency of 0.01, the value used in our linkage analysis. Setting the type I error rate at Table 5 Frequency of CCK alleles in 77 triads. Transmitted alleles are those found in the probands, while non-transmitted alleles are those constructed from the alleles of the parents of the proband that were not transmitted to the proband. For alleles, 2 = 0.14, df = 1, NS
Allele
Transmitted Non-transmitted
Molecular Psychiatry 5% and the attributable risk (ie, the percentage of disease prevalence attributable to the allele of interest) to about 20%, we obtain 95%, 94%, and 94% power for multiplicative, additive, and dominant modes of inheritance (MOIs), respectively. Reducing the attributable risk to about 12%, we obtain power levels of 80%, 78%, and 77% for the same respective modes of inheritance. For the recessive MOI, our sample of 77 triads had poor power (less than 10%) to detect evidence of linkage disequilibrium for the same genetic models considered above. Obviously, in calculating the power, one needs to assume a mode of inheritance, which is not known; however, the models we assumed in our calculations can be considered 'complex' in the sense that they have a small genetic effect, such as the case when the attributable risk is 12%. Likewise, our analysis of promoter SNP in the CCK gene also showed no significant association or linkage to panic disorder. This SNP is an appealing candidate, given that the C/T transition in the highly conserved Sp1 transcription factor-binding site would be expected to have some effect on CCK transcription initiation, especially since deletion of the entire Sp1 site leads to decreased transcription. 42 Sertraline, an effective medication in the treatment of panic disorder, has been reported to influence the regional distribution of stress-induced CCK mRNA. 43 Our CCK results are similar to those of Kennedy et al. As with the CCKBR results, differences between cases and controls may explain the discrepancy between our CCK results and those of Wang et al. In their report, the frequency of the T allele varied with choice of control population, from 8.3% in 247 parents of children with cleft palate, to 28.3% among 99 newborns, to 13.9% in 79 ophthalmology patients. Less variability in the frequency of the T allele has been described using a British Caucasian population, 44 where no significant difference was seen between controls (9%), bipolar probands (11%), and schizophrenia probands (7%). This polymorphism has been investigated in alcoholism in the Japanese, where the T allele is much more frequent (ෂ30%). Using a case-control approach, one study found no association between alcoholism and the CCK SNP, 45 while another study reported that alcoholics with delirium tremens differed from controls in the distribution of the T allele while other alcoholics did not. 46 Although the work described here provides no evidence for any role of CCK-related polymorphisms in panic disorder in our study population, other studies that focus on different populations, or sub-groups such as those who panic in response to the panicogenic peptide CCK-4 might still be warranted.
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